Bedaquiline;Delamanid/Strong 3A4 Inhibitors that Prolong QT Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines can slow down how quickly your body processes bedaquiline and delamanid. Bedaquiline and delamanid may affect your heart's rhythm. Other drugs can have the same effect.
What might happen:
The amount of bedaquiline or delamanid in your blood may increase and cause more side effects than expected, including changes to your heart rhythm, which may be life-threatening. Elevated levels of bedaquiline may also cause problems with your liver.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change your medicine and/or perform an electrocardiogram (ECG). Let your doctor know right away if you notice any irregular heartbeat or have any dizziness or fainting episodes or if you develop unexplained nausea or vomiting, stomach pain, fever, weakness, itching, unusual tiredness, loss of appetite, light colored bowel movements, dark colored urine, or yellowing of the skin or whites of your eyes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Sirturo (bedaquiline) US prescribing information. Janssen Therapeutics May, 2020.
- 2.Deltyba (delamanid) EMA summary of products characteristics. Otsuka Novel Products GmbH April 28, 2014.
- 3.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
- 4.Kaletra (lopinavir/ritonavir capsules) US prescribing information. Abbott Laboratories September, 2016.
- 5.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
- 6.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.